Anti-D Rh0 immunoglobulin - Kamada

Drug Profile

Anti-D Rh0 immunoglobulin - Kamada

Alternative Names: Anti-D immunoglobulin - Kamada; KamRho; KamRho (D) IM; KamRho (D) IV

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kamada
  • Developer Kamada; Vitel Laboratorios
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 09 May 2017 Preregistration for Haemolytic disease of newborn (Prevention) in Mexico (IM)
  • 18 Apr 2017 OncBioMune Pharmaceuticals announces intention to submit MAA to COFEPRIS for haemolytic disease of newborn (Prevention) in April 2017
  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top